GeneFerm Biotechnology Co., Ltd. (1796.TWO)

GeneFerm Biotechnology Co., Ltd. (1796.TWO) — VMCI valuation read

Headline read on 1796.TWO: VMCI of 51/100 versus a Healthcare sector median of 50. The 1-point above-median position is what makes GeneFerm Biotechnology Co., Ltd. a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 1796.TWO: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 1796.TWO: value (1796.TWO trades at 19.0x earnings, 6% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 2.3x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

1796.TWO fell 1.1% over the trailing 7 days, with a -8.0% read on a 30-day basis.